YTHDF1 and neoplasm: Knockdown of YTHDF1 could improve the crosspresentation ability of dendritic cells in mouse melanoma, and when combined with a PD-L1 checkpoint inhibitor, the tumor was almost completely controlled (Han et al., 2019).